ArticleFrontiers in medicine2025
Effect of low-dose ciprofol on postoperative nausea and vomiting following gynecologic day surgery: a randomized controlled trial.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Effects of Ciprofol- versus Remimazolam-Based Total Intravenous Anesthesia on Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy: A Randomized Controlled Trial.Drug design, development and therapy · 2026Trial
- Efficacy and safety of ciprofol for general anesthesia in pediatric strabismus correction surgery: a prospective, randomized, double-blind, non-inferiority study.Frontiers in medicine · 2026Trial
- Interpretable machine learning for postoperative nausea and vomiting prediction in elderly orthopedic patients: a comparative study.BMC medical informatics and decision making · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Low-dose propofol has a preventive effect on postoperative nausea and vomiting (PONV). Ciprofol is a new short-acting GABA Patients and methods: In this study, this study enrolled 75 patients undergoing gynecological ambulatory surgery under general anesthesia, and randomly divided the patients into ciprofol group and normal saline control group. Both groups received remimazolam (6 mg/kg/h) until asleep, then alfentanil (20 μg/kg) and mivacurium (0.2 mg/kg) intravenous, followed by maintenance infusions of remimazolam and alfentanil. Five minutes after the start of the surgery, the ciprofol group was given 2 mL of ciprofol (5 mg) and the control group was given 2 mL of normal saline. The primary outcome measure was the incidence of PONV in the PACU. Secondary outcomes included the incidence of emetic episodes or nausea in the PACU and within 24 h, anesthetic time, wake-up time, and administered doses of remimazolam and alfentanil. Safety outcomes encompassed hypotension, hypertension, bradycardia, and tachycardia. Results: The incidence of PONV in the PACU was significantly lower in the ciprofol group compared to the control group (16.2% vs 52.6%; RR=0.31; 95% CI, 0.14-0.68; ARR=0.364; Conclusion: Low-dose ciprofol can effectively prevent PONV in PACU after gynecological day surgery under general anaesthesia remazolam combined with afentanil, but its effect is limited and cannot reduce the incidence of emetic episodes or nausea within 24 h after surgery. Clinical trial registration: https://www.chictr.org.cn, identifier ChiCTR2300077247.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.